Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency

European Journal of Endocrinology

Volumn 150, Issue 5, 2004, Pages 671-679

  Abrahamsen, B ^d   Nielsen, T L ^d   Hangaard, J ^d   Gregersen, G ^a   Vahl, N ^b   Korsholm, L ^c   Hansen, T B ^d   Andersen, M ^d   Hagen, C ^d  

^a ESBJERG HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; ARTHRALGIA; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENDER; GROWTH HORMONE DEFICIENCY; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LEAN BODY WEIGHT; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ADULT; AGE OF ONSET; BODY COMPOSITION; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; LIPOPROTEINS; MALE; METABOLISM, INBORN ERRORS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; THINNESS;

EID: 2942733167     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500671     Document Type: Article

References (38)

1. Carroll PV, Christ ER, Bengtsson BÅ, Carlsson L, Christiansen JS, Clemmons D et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Journal of Clinical Endocrinology and Metabolism 1998 83 382-393.
2. Cuneo RC, Salomon F, Watts GF, Hesp R & Sonksen PH. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993 42 1519-1523.
3. De Boer H, Blok GJ, Voerman HJ, Phillips M & Schouten JA. Serum lipid levels in growth hormone-deficient men. Metabolism 1994 43 199-203.
4. Beshyah SA, Henderson A, Niththyananthan R, Skinner E, Anyaoku V, Richmond W et al. The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. Journal of Clinical Endocrinology and Metabolism 1995 80 356-363.
5. Rosen T & Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 336 285-288.
6. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA & Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. PNAS 1992 89 6983-6987.
7. Russell-Jones DL, Watts GF, Weissberger A, Naoumova R, Myers J, Thompson GR et al. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clinical Endocrinology 1994 41 345-350.
8. Murray RD & Shalet SM. Adult growth hormone replacement: lessons learned and future direction. Journal of Clinical Endocrinology and Metabolism 2002 87 4427-4428.
9. The Growth Hormone Research Society, Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 379-381.
10. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. http://www.wma.net/e/policy/pdf/17c.pdf. 2000.
11. Vahl N, Hansen TB, Klausen IB, Jurik AG, Hagen C & Christiansen JS. The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study. International Journal of Obesity 1998 22 529-536.
12. Jorgensen JO, Vahl N, Hansen TB, Thuesen L, Hagen C & Christiansen JS. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalisation of body composition. Clinical Endocrinology 1996 45 681-688.
13. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. Journal of Clinical Endocrinology and Metabolism 1994 78 744-752.
14. Andersen M, Hansen TB, Stoving RK, Bertelsen J, Hangaard J, Petersen PH et al. The pyridostigmine-growth-hormone-releasing-hormone test in adults. The reference interval and a comparison with the insulin tolerance test. Endocrinology and Metabolism 1996 3 197-206.
15. Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
16. Murray RD, Wieringa GE, Lissett CA, Darzy KH, Smethurst LE & Shalet SM. Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome. Clinical Endocrinology 2002 56 525-532.
17. Florakis D, Hung V, Kaltsas G, Coyte D, Jenkins PJ, Chew SL et al. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clinical Endocrinology 2000 53 453-459.
18. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002 106 388-391.
19. Christ ER, Cummings MH & Russell-Jones DL. Dyslipidaemia in adult growth hormone (GH) deficiency and the effect of GH replacement therapy: a review. Trends in Endocrinology and Metabolism 1998 9 200-206.
20. Leese GP, Wallymahmed M, VanHeyningen C, Tames F, Wieringa G & MacFarlane IA. HDL-cholesterol reductions associated with adult growth hormone replacement. Clinical Endocrinology 1998 49 673-677.
21. Salomon F, Cuneo RC, Hesp R & Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New England Journal of Medicine 1989 321 1797-1803.
22. Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy L, Atkinson AB et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clinical Endocrinology 1992 36 45-52.
23. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. Journal Clinical Endocrinology and Metabolism 1998 83 107-116.
24. Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. Journal of Clinical Endocrinology and Metabolism 1993 76 309-317.
25. Ezzat S, Fear S, Gaillard RC, Gayle C, Landy H, Marcovitz S et al. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 2002 87 2725-2733.
26. Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM & Trainer PJ. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clinical Endocrinology 2002 57 59-64.
27. Hayes FJ, Fiad TM & McKenna TJ. Gender difference in the response of growth hormone (GH)-deficient adults to GH therapy. Metabolism 1999 48 308-313.
28. Lissett CA & Shalet SM. The impact of dose and route of estrogen administration on the somatotropic axis in normal women. Journal of Clinical Endocrinology and Metabolism 2003 88 4668-4672.
29. Jensen LB, Vestergaard P, Hermann AP, Gram J, Eiken P, Abrahamsen B et al. Hormone replacement therapy reduces weight gain, and dissociates fat mass and bone mass in early postmenopausal women: A randomised controlled five-year clinical trial. The Danish Osteoporosis Prevention study (DOPS). Journal of Bone and Mineral Research 2003 18 333-342.
30. McManus J, McEneny J, Thompson W & Young IS. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. Atherosclerosis 1997 135 73-81.
31. Wolfe BM, Koval JJ & Nisker JA. Effects of adding C-19 versus C-21 progestin to conjugated estrogen in moderately hypercholesterolemic postmenopausal women. American Journal of Obstetrics and Gynecology 1998 178 787-792.
32. Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in post-menopausal women. Archives of Internal Medicine 2000 160 3315-3325.
33. O'Sullivan AJ, Crampton LJ, Freund J & Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. Journal of Clinical Investigation 1998 102 1035-1040.
34. Orme SM, McNally RJ, Cartwright RA & Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734.
35. Nikkila EA & Pelkonen R. Serum lipids in acromegaly. Metabolism 1975 24 829-838.
36. Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B. Porretti S, Epaminonda P et al. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Experimental Clinical Endocrinology and Diabetes 2000 108 486-492.
37. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G & Manzato E. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 2000 151 551-557.
38. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. Journal of Clinical Endocrinology and Metabolism 2001 86 1551-1557.